1339:HKEXThe People's Insurance Company (Group) of China Limited Analysis
Data as of 2026-03-14 - not real-time
HK$6.09
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
The People's Insurance Company (Group) of China Limited trades at a trailing P/E of 5.44, far below the industry average of 16.35, and its DCF‑derived fair value of HK$9.76 suggests an upside of roughly 36%. With a dividend yield of 3.45% and a modest payout ratio of 18%, the dividend appears highly sustainable given strong operating cash flow of HK$102.8 bn and a low debt‑to‑equity of 38%. Revenue growth of 14.3% and solid ROE of 18% provide a credible growth narrative, while the stock is currently priced at HK$6.09, below its 20‑day SMA of 6.47 and 200‑day SMA of 6.54.
Technical indicators show a bearish MACD, a sub‑50 RSI at 35, and decreasing volume, indicating short‑term pressure near the support level of HK$6.06. Nonetheless, the combination of deep valuation discount, strong cash generation, and attractive dividend supports a medium‑ to long‑term buy case, provided investors are comfortable with the modest regulatory and geographic headwinds inherent to the Chinese insurance sector.
Technical indicators show a bearish MACD, a sub‑50 RSI at 35, and decreasing volume, indicating short‑term pressure near the support level of HK$6.06. Nonetheless, the combination of deep valuation discount, strong cash generation, and attractive dividend supports a medium‑ to long‑term buy case, provided investors are comfortable with the modest regulatory and geographic headwinds inherent to the Chinese insurance sector.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term moving averages
- Bearish MACD and RSI near oversold
- Decreasing trading volume
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation gap vs DCF fair value
- Strong cash flow and low payout ratio
- Robust revenue growth and ROE
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustainable dividend supported by ample cash reserves
- Stable balance sheet with moderate leverage
- Long‑run upside potential as market re‑rates the business
Key Metrics & Analysis
Financial Health
Revenue Growth14.30%
Profit Margin8.38%
P/E Ratio5.4
ROE18.05%
ROA3.13%
Debt/Equity37.99
P/B Ratio0.8
Op. Cash FlowHK$102.8B
Free Cash FlowHK$10.3B
Industry P/E16.4
Technical Analysis
TrendNeutral
RSI35.3
SupportHK$6.06
ResistanceHK$7.05
MA 20HK$6.47
MA 50HK$6.70
MA 200HK$6.54
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
Fair ValueHK$9.76
Target PriceHK$8.28
Upside/Downside35.96%
GradeUndervalued
TypeValue
Dividend Yield3.45%
Risk Assessment
Beta0.13
Volatility34.36%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.